Ipsen to acquire U.S.-based Epizyme for $247 million.
June 27, 2022 at 02:12 AM EDT
The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
San Anselmo | San Anselmo News | San Anselmo Travel | Restaurants | Nightlife | Things To Do | Shopping | Calendar | Directory | Real Estate | Blog | More
|